As Australia’s first regulated Class 2 donor-derived microbiome therapy listed on the ARTG, BiomeBank guarantees stringent multi-stage donor screening and expert nationwide support throughout the process.
Our current product, BIOMICTRA®, is the world’s first microbiome-based therapy regulated as a biological.
BIOMICTRA® is donor-derived after stringent screening, and is available in a frozen syringe-based formulation for colonoscopy and enema delivery.
BiomeBank is reformulating BIOMICTRA® into capsule form with the encapsulated product expected be available through hospitals and pharmacies in the near future.
BIOMICTRA® is manufactured in a purpose built Australian GMP facility, following rigorous quality-controlled screening and manufacturing processes.
BIOMICTRA® is currently supplied to hospitals and clinics throughout Australia and can be administered by healthcare professionals.
Donor derived Faecal Microbiota Transplantation (FMT) is a highly effective therapy for the treatment of recurrent Clostridioides difficile infection — the most common cause of healthcare associated diarrhoea. Multiple randomised controlled trials and meta-analyses of these studies have demonstrated the superiority of FMT over antibiotic therapy alone for the treatment of recurrent C.difficile infection.
While FMT is now the standard of care for recurrent C. difficile infection in most international guidelines, evidence is emerging for its use in other diseases.
BiomeBank’s co-founders Associate Professor Sam Costello and Professor Rob Bryant have been pioneers in this field and BiomeBank is facilitating a number of clinical trials in a range of diseases with collaborating organisations.
Current Treatment (Antibiotics) vs Faecal Microbial Transplantation (FMT)
CONSORTIOME® is BiomeBank’s proprietary platform for next-generation microbial therapeutics – delivering reproducible, high-quality interventions at scale – and unlocking the next frontier in microbiome medicine. Learn more about our breakthrough co-culturing platform and how we generate an artificial human gut microbial community in a bioreactor.
